These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37989343)

  • 1. [A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation 
and Literature Review].
    Miao Y; Wang Y; Li P; Tan M; Wen T; Wang C; Xie S
    Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):795-800. PubMed ID: 37989343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.
    Luo Z; Luo C; Zhou R; Xiao Y; Wang T
    Anticancer Drugs; 2023 Sep; 34(8):939-941. PubMed ID: 37227041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
    Long X; Qin T; Lin J
    Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
    Li T; Wang S; Ying J; Wang Y; Hu X; Hao X; Xu Z; Xing P; Li J
    Thorac Cancer; 2021 Nov; 12(21):2924-2932. PubMed ID: 34549528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.
    Qin BD; Jiao XD; Yuan LY; Liu K; Wang Z; Qin WX; Zang YS
    Onco Targets Ther; 2018; 11():4739-4745. PubMed ID: 30127622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of lung adenocarcinoma complicated with a rare compound
    Li L; Huang S; Qin L; Yan N; Shen S; Li X
    Front Pharmacol; 2023; 14():1257592. PubMed ID: 37719840
    [No Abstract]   [Full Text] [Related]  

  • 8. Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
    Smith JT; Puri S; Akerley W
    Clin Lung Cancer; 2023 Jun; 24(4):360-361. PubMed ID: 36935243
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.
    Zhou B; Wang Y; Liao H; Li B
    Medicine (Baltimore); 2022 Aug; 101(33):e30080. PubMed ID: 35984165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A L833V/H835L
    Yang X; Yao Y; Zhu Q
    Heliyon; 2022 Dec; 8(12):e12080. PubMed ID: 36531621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.
    Cosso F; Roviello G; Catalano M; Botteri C; Comin CE; Castiglione F; Ferrari K; Baldini E; Mini E
    Anticancer Drugs; 2024 Jan; 35(1):76-80. PubMed ID: 37067984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
    Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
    BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
    Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
    Li J; Zhu L; Stebbing J; Peng L
    J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.